Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.
1. An isolated antibody that binds SEQ ID NO:3 with an affinity that is at least about 10 fold greater than the affinity with which the antibody binds SEQ ID NO:4 and SEQ ID NO:5, wherein the antibody inhibits aggregation of cells that express a mammalian Cadherin-11 protein, and wherein the antibody binds an epitope that comprises SEQ ID NO:11.
2. The isolated antibody of claim 1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a humanized antibody, a chimeric antibody, a single chain antibody, and an antibody fragment.
3. The isolated antibody of claim 2 , wherein the antibody is an antibody fragment.
4. The isolated antibody of claim 3 , wherein the antibody fragment is selected from the group consisting of an Fab, an Fab′, an F(ab′) 2 and an scFv.
5. The isolated antibody of claim 1 , wherein the antibody binds an epitope that is present in SEQ ID NO:10.
6. An antibody produced by hybridoma H1M1 (ATCC Patent Deposit Designation PTA-9699).
7. An antibody produced by hybridoma H14 (ATCC Patent Deposit Designation PTA-9701).
8. An isolated antibody comprising an antibody variable heavy chain region comprising SEQ ID NO:51 and an antibody variable light chain region comprising SEQ ID NO:56, wherein the antibody specifically binds an EC1 domain of a human Cadherin-11 protein and inhibits aggregation of cells that express said mammalian human Cadherin-11 protein.
9. The isolated antibody of claim 8 , wherein the antibody is a humanized antibody.
10. An isolated antibody that specifically binds an EC1 domain of a human Cadherin-11 protein, comprising an antibody variable heavy chain region having:
a) a CDR1 consisting of SEQ ID NO:52;
b) a CDR2 consisting of SEQ ID NO:53; and
c) a CDR3 consisting of SEQ ID NO:54; and
an antibody variable light chain region having:
d) a CDR1 consisting of SEQ ID NO:57;
e) a CDR2 consisting of SEQ ID NO:58; and
f) a CDR3 consisting of SEQ ID NO:59;
wherein the antibody inhibits aggregation of cells that express said human Cadherin-11 protein.
11. The isolated antibody of claim 10 , wherein the antibody is a humanized antibody.